HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Over 15 years' experience in both finance and healthcare, covering clinic operations, investment and equity research in both China and overseas.

Goldlion Holdings (533 HK) Privatization - Updates on Valuation Outlook Based on 2024 Results

Goldlion Holdings (533 HK) Privatization - About the Deal Break and the Valuation Outlook

Ping An Good Doctor (1833 HK) - The Mandatory General Offer and DeepSeek Story May Not Turn the Tide

Shanghai Henlius Biotech (2696 HK)- LVC Is Betting on Higher Valuation Upside Due to Business Update

Tam Jai International (2217 HK) Privatization - The Offer Price Is Good

China Healthcare Weekly (Feb.23)-Ping An Good Doctor Shares Surge, China Healthcare Has Bottomed Out

Pre-IPO MIXUE Group (PHIP Updates) - Some Points Worth the Attention

Equity Bottom-Up

<ul>
<li>In recent years, Goldlion is facing performance headwinds. Both revenue and net profit have shown a downward trend due to declining consumption, real estate crisis and unfavorable external factors.</li>
<li>In short term, the weak consumer confidence and market momentum are unlikely to improve. Goldlion's performance may gradually pick up in 2026 and 2027 but is still in downward trend.</li>
<li>Considering the low trading liquidity, weak fundamentals, uncertainties on performance brought by Goldlion's potential strategic transformation and  the concerns on the outlook, we think the Cancellation Price is acceptable.</li>
</ul>


In recent years, Goldlion is facing performance headwinds. Both revenue and net profit have shown a downward trend due to declining consumption, real estate crisis and unfavorable external factors.
In short term, the weak consumer confidence and market momentum are unlikely to improve. Goldlion's performance may gradually pick up in 2026 and 2027 but is still in downward trend.
Considering the low trading liquidity, weak fundamentals, uncertainties on performance brought by Goldlion's potential strategic transformation and  the concerns on the outlook, we think the Cancellation Price is acceptable.


Goldlion Holdings (533 HK) Privatization - The Offer Price Is Acceptable